Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests £115 million ($144 million) in new research center.
University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research center on the premises of the University of Oxford.
The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers, based in an Oxford University research center. The total investment from Novo Nordisk is expected to be around 1 billion Danish kroner (£115 million/$144 million) over a period of 10 years. The center will focus on innovation within early stage research that has potential to substantially impact future treatment of type 2 diabetes and its complications.
“This collaboration brings together some of the world’s sharpest minds in the field of diabetes to seek new targets for therapeutic innovation. It combines Novo Nordisk’s 90 years’ experience in developing treatments for diabetes with the expertise of world leading scientists from the University of Oxford. Our vision is that the unique combination of industrial and academic know-how will eventually lead to a new generation of treatments to improve the lives of people with type 2 diabetes,” said Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk, .
The collaboration will actively seek to encourage cross-fertilization of ideas between academic researchers from the University of Oxford and researchers employed by Novo Nordisk with funds to sponsor the collaborative research.
Sir John Bell, Regius Professor of Medicine, University of Oxford, said: “We see the collaboration with Novo Nordisk as an outstanding opportunity to mix competence embedded at our campus with Novo Nordisk’s groundbreaking research and results in diabetes. This collaboration underlines the importance of shared research and cutting-edge science across boundaries. Employees at Novo Nordisk Research Centre Oxford and researchers at the University of Oxford will have the opportunity for daily interaction to share knowledge and insights that will potentially produce new medicines for people living with type 2 diabetes and its complications.”
James D. Johnson, professor, Ph.D., has been appointed head of the Novo Nordisk Research Center Oxford. He is a researcher in the fundamental biology of pancreatic islets, insulin action, diabetes and related conditions. Johnson is currently professor at the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia.
Novo Nordisk and University of Oxford have had a collaboration since 2013 through the International Postdoctoral Fellowship Program. The program was extended in 2015 and will include up to 32 fellows.
(Source: Novo Nordisk)